Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
31
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Heart failure (HF) is a complex syndrome commonly categorized into two main phenotypes [left ventricular ejection fraction (LVEF) below or above 40%], and although empagliflozin is the first approved medication with proven clinical effectiveness for both phenotypes, its cost-effectiveness of treating the entire HF population remains unknown. The analysis was performed utilizing two preexisting, LVEF phenotype-specific cost-effectiveness models to estimate the cost-effectiveness of empagliflozin in adults for the treatment of symptomatic chronic HF, irrespective of ejection fraction (EF). The results of the phenotype-specific models were combined using a population-weighted approach to estimate the deterministic and probabilistic incremental cost-effectiveness ratios (ICERs). Based on combined results, empagliflozin + standard of care (SoC) is associated with 6.13 life-years (LYs) and 3.92 quality-adjusted life-years (QALYs) compared with 5.98 LYs and 3.76 QALYs for SoC alone over a lifetime, resulting in an incremental difference of 0.15 LYs and 0.16 QALYs, respectively. Total lifetime healthcare costs per patient are £15 246 for empagliflozin + SoC and £13 982 for SoC giving an incremental difference of £1264. The ICER is £7757/QALY, which is substantially lower than the willingness-to-pay (WTP) of £30 000 per QALY used by NICE. The results of the probabilistic sensitivity analyses are in line with the deterministic results. Empagliflozin is the first efficacious, approved, and cost-effective treatment option for all HF patients, irrespective of EF. The combined ICER was consistently below the WTP threshold. Therefore, empagliflozin offers value for money for the treatment of the full HF population in England.
Identifiants
pubmed: 37577867
doi: 10.2459/JCM.0000000000001532
pii: 01244665-202310000-00011
pmc: PMC10481921
doi:
Substances chimiques
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-764Informations de copyright
Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93:1137–1146.
Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol 2015; 6:187–214.
Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015; 101:1182–1189.
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014; 171:368–376.
Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014−2020). Pharmacoeconomics 2020; 38:1219–1236.
Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord 2018; 18:74.
Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001; 3:283–291.
Gielen V, Alexopoulos S, Hudson P, Mitchell S. PCV143 − resource use in chronic heart failure in the UK: a systematic review. Value Health 2016; 19:A662.
Foundation BH. Heart failure hospital admissions rise by a third in five years. 2022. https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2019/november/heart-failure-hospital-admissions-rise-by-a-third-in-five-years . [Accessed 22 August 2022]
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J 2020; 25:5.
Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018; 391:572–580.
Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep 2014; 11:404–415.
Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015; 372:1333–1341.
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017; 3:7–11.
Beggs SAS, McDonagh TA, Gardner RS. Chronic heart failure: epidemiology, investigation and management. Medicine 2018; 46:594–600.
Hajouli S, Ludhwani D. Heart failure and ejection fraction. StatPearls: StatPearls Publishing; 2022.
Aldaas OM, Igata S, Raisinghani A, Kraushaar M, DeMaria AN. Accuracy of left ventricular ejection fraction determined by automated analysis of handheld echocardiograms: a comparison of experienced and novice examiners. Echocardiography 2019; 36:2145–2151.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385:1451–1461.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413–1424.
EMA. Jardiance: summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance . [Accessed 27 July 2022]
FDA. Jardiance. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf . [Accessed 22 August 2022]
Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012; 32:667–677.
NICE. Empagliflozin for treating chronic heart failure with reduced ejection fraction. https://www.nice.org.uk/guidance/ta773/chapter/1-Recommendations . [Accessed 27 July 2022]
Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35:1245–1255.
Eurostat. Harmonised Index of Consumer Prices. 2022. https://ec.europa.eu/eurostat/web/hicp/data/main-tables . [Accessed 27 July 2022]
NICE. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from an English Population Study. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/estimating-the-relationship-betweenE-Q-5D-5L-and-EQ-5D-3L.pdf . [Accessed 22 August 2022]
Packer M, Butler J, Zannad F, et al. Empagliflozin and major renal outcomes in heart failure. N Engl J Med 2021; 385:1531–1533.
CPRD. Incidence, prevalence, resource use and clinical outcomes of heart failure in England: a linked descriptive analysis of primary and secondary care (PULSE). https://cprd.com/protocol/incidence-prevalence-resource-use-and-clinical-outcomes-heart-failure-england-linked . [Accessed 27 July 2022]
Wu E, Pellissier J, Kvamme M, Irgens K. A holistic approach to evaluate the cost-effectiveness of pembrolizumab with multiple indications: a Norway-based example. Value Health 2018; 21:S7.
Jakobsen M, Holst-Kristensen A. PDG40: the potential of a weighted average ICER as a supplementary decision tool when assessing the cost-effectiveness of MULTI-Indication Pharmaceuticals. Value Health 2020; 23:S526.